ProQR Therapeutics NV Company Profile (NASDAQ:PRQR)

Analyst Ratings

Consensus Ratings for ProQR Therapeutics NV (NASDAQ:PRQR) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $19.50 (312.26% upside)

Analysts' Ratings History for ProQR Therapeutics NV (NASDAQ:PRQR)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016Chardan CapitalInitiated CoverageNeutral$4.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016JMP SecuritiesLower Price TargetMarket Outperform$24.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2016HC WainwrightReiterated RatingBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2015Leerink SwannReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/15/2014Deutsche Bank AGInitiated CoverageBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2014Jefferies GroupInitiated CoverageOutperform$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for ProQR Therapeutics NV (NASDAQ:PRQR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/17/2016        
5/18/2016Q1($0.41)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2016Q4($0.35)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/23/2015Q3($0.36)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/19/2015($0.32)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/21/2015($0.29)$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015($0.27)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/24/2014($1.00)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ProQR Therapeutics NV (NASDAQ:PRQR)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ProQR Therapeutics NV (NASDAQ:PRQR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ProQR Therapeutics NV (NASDAQ:PRQR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for ProQR Therapeutics NV (NASDAQ:PRQR)
DateHeadline
07/19/16 06:00 AMProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis - [GlobeNewswire] - LEIDEN, the Netherlands, July 19, 2016-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases ...
06/21/16 08:19 AMProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC - [at noodls] - LEIDEN, the Netherlands, June 21, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment ...
06/20/16 04:50 AMCoverage initiated on ProQR Therapeutics by Chardan Capital Markets -
06/08/16 05:03 PMProQR Therapeutics NV :PRQR-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/01/16 06:23 AMProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference - [at noodls] - LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that the company will present pre-clinical data for QR-010 at the 39European Cystic Fibrosis ...
06/01/16 06:23 AMProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation - [at noodls] - LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the company's investigational drug QR-110 has received orphan drug designation (ODD) ...
06/01/16 06:04 AM7:04 am ProQR Therapeutics confirms that its investigational drug QR-110 has received orphan drug designation from both the FDA and the EMA for the treatment of Leber's congenital amaurosis Type 10 -
05/18/16 06:42 AMProQR Announces Results for the First Quarter of 2016 - [at noodls] - LEIDEN, the Netherlands, May 18, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment ...
05/18/16 06:23 AMProQR reports 1Q loss -
02/17/16 06:19 AMProQR reports 4Q loss -
02/03/16 06:00 AMProQR to Present at the Leerink Partners Global Healthcare Conference - [GlobeNewswire] - LEIDEN, the Netherlands, Feb. 03, 2016-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases ...
12/22/15 07:33 AMWhy ProQR Therapeutics (PRQR) Stock Might be a Great Pick -
12/14/15 08:24 PMHedge Funds Aren’t Crazy About ProQR Therapeutics NV (PRQR) Anymore -
12/09/15 07:45 AMProQR Therapeutics (PRQR) Rises: Stock Up 6.1% in Session -
12/08/15 12:09 PMPROQR THERAPEUTICS N.V. Financials -
11/30/15 06:00 AMProQR Announces R&D Day and Provides Update on Innovation Portfolio - [GlobeNewswire] - LEIDEN, Netherlands, Nov. 30, 2015-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such ...
11/24/15 07:50 AMProQR Therapeutics (PRQR) Falls: Stock Goes Down 24.8% -
11/23/15 06:02 AMProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials - [at noodls] - ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials
11/23/15 05:39 AMProQR reports 3Q loss -
10/01/15 06:18 AMProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences - [at noodls] - LEIDEN, Netherlands, Oct. 1, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that the company will present abstracts with pre-clinical data for its cystic fibrosis program ...
09/14/15 06:15 AMProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment - [at noodls] - LEIDEN, the Netherlands, Sept. 14, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that PQ-010-002 is open for enrollment. The primary objective of PQ-010-002 is to estimate ...
08/19/15 07:38 AMProQR Announces Results for the Second Quarter of 2015 - [at noodls] - ProQR Announces Results for the Second Quarter of 2015
08/19/15 07:15 AMProQR reports 2Q loss -

Social

About ProQR Therapeutics NV

ProQR Therapeutics NV logoProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, is an oligonucleotide.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PRQR
  • CUSIP:
Key Metrics:
  • Previous Close: $4.73
  • 50 Day Moving Average: $4.81
  • 200 Day Moving Average: $5.00
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $110.42M
  • Beta: 0.98
  • Current Year EPS Consensus Estimate: $-1.70 EPS
  • Next Year EPS Consensus Estimate: $-1.96 EPS
Additional Links:
ProQR Therapeutics NV (NASDAQ:PRQR) Chart for Wednesday, July, 27, 2016